TD Cowen analyst Ritu Baral initiates coverage on Opus Genetics (NASDAQ: IRD) with a Buy rating.The analyst comments "We are ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot New Coverage New Coverage